Doses, Routes, and Half-Lives — As the Studies Recorded Them

The short version — what dose numbers mean here

Every dose figure on this page comes from a published study and is labelled with the species, route, and context in which it was used. 'Intraperitoneal' (IP) means injected into the body cavity of a rat or mouse — the most common method in animal studies. 'Micrograms per kilogram' (μg/kg) or 'nanograms per kilogram' (ng/kg) expresses dose relative to body weight, which is how animal-study doses are reported.

These numbers are not recommendations for human use. BPC-157 has no approved human dose, no validated allometric scaling from rodent to human, and the only human pilot data that specify a dose used 10 mg and 20 mg given intravenously to two adults in a safety study — figures chosen empirically, not from any published dose-rationale methodology.

The pharmacokinetics summary (how long it stays in the body, how much is absorbed by different routes) comes from a formal 2022 rat-and-dog study that is the most rigorous pharmacokinetic characterization published to date. It is cited with its reference number throughout.

Pharmacokinetics — what is known

The most detailed pharmacokinetic characterization of BPC-157 to date comes from a 2022 paper in Frontiers in Pharmacology by He et al., which used rats and beagle dogs across multiple routes and dose levels ^[5].

The intravenous half-life was found to be 15.2 minutes in rats and 5.27 minutes in beagle dogs. Intramuscular bioavailability was 14–19% in rats and 45–51% in dogs, with a Tmax (time to peak plasma concentration) of approximately three minutes in rats after IM administration. Six metabolites were identified (designated M1 through M6), consisting of small peptide fragments and single amino acids excreted primarily via urine and bile. Pharmacokinetics were linear across all doses studied, indicating no saturation of metabolic pathways at the doses tested.

This short plasma half-life — less than thirty minutes by IV in both species — creates an observation that has become a recurring methodological point in the BPC-157 literature: the compound is cleared rapidly from plasma, yet its therapeutic effects in animal models routinely persist for weeks to months. A 2025 narrative review proposed that this dissociation is consistent with a biological-switch model — BPC-157 activates a self-sustaining downstream gene-expression cascade (Akt1, Nos3, Vegfa, Src, FAK, and at least fourteen other genes upregulated within ten minutes of wound application) that continues to drive repair signaling after the parent compound is metabolized ^[18].

An older study reported a half-life estimate of approximately sixty-six to sixty-nine hours in rodents under different assay conditions. The current understanding from the He et al. pharmacokinetic study — which used validated UHPLC methods and stable isotope standards — suggests the earlier estimate likely reflected the persistence of biological activity rather than the persistence of the parent compound itself ^[5]. Both numbers appear in the research literature; this distinction matters for any attempt to interpret them.

For the antidoping context: a 2023 metabolomics study using stable-isotope-labeled BPC-157 and UHPLC-HRMS identified nine metabolites in human liver microsomes and validated a urine detection method capable of identifying BPC-157 and five major metabolites at detection limits of 0.01–0.11 ng/mL ^[19]. This work was conducted specifically to support WADA anti-doping control programs following the compound's 2022 prohibition under S0.

Doses recorded in preclinical studies

The range of doses used across the published BPC-157 preclinical literature is notably wide, which itself carries a methodological implication: findings at vastly different doses in different species and models are difficult to compare directly, and no dose-optimization study for human translation has been conducted.

In standard rat healing studies, the most common intraperitoneal doses are 1–10 μg/kg, consistent across gut, tendon, wound, and vascular injury models. The minimum effective dose documented across multiple rodent models is 10 ng/kg — roughly one thousand times lower than the higher end of the intraperitoneal range — administered both intraperitoneally and orally via drinking water ^[4]. Drinking water administration has been studied at approximately 0.16 μg/mL, which corresponds to roughly 1.9 μg/kg per day in a standard-weight rat.

For wound healing research, topical cream formulations have been studied at 1 μg/g, producing effects in excisional, incisional, burn, and diabetic wound models ^[7]. For spinal cord injury research, 200 μg/kg was used intraperitoneally — the highest dose documented in rodent efficacy studies — alongside a 2 μg/kg arm that also showed significant effects ^[6]. For ischemia-reperfusion organ protection, 20 μg/kg intraperitoneally in rats was the dose associated with significant histopathological improvements across kidney, lung, and liver tissue ^[9].

In the two human pilot studies that specified a dose: the IV pharmacokinetic safety study administered 10 mg on day one and 20 mg on day two to two healthy adults over one-hour infusions ^[15], and the interstitial cystitis pilot administered 10 mg intravesicularly to twelve patients ^[14]. These human doses are not directly translatable from rodent μg/kg data without validated allometric scaling, and no such scaling validation has been published. The Sports Health systematic review noted this gap explicitly ^[16].

Routes of administration studied

The routes documented in the published literature are: intravenous (IV), intramuscular (IM), intraperitoneal (IP — the most common route in rodent studies), oral gavage, administration via drinking water, topical cream, rectal enema (the route used in the IBD Phase II trial), intra-articular injection (the knee-pain human pilot), and intravesicular injection (the interstitial cystitis human pilot).

Oral bioavailability has not been formally quantified in the way IM bioavailability has, but rodent gastrointestinal models confirm bioactivity following oral administration at 0.16 μg/mL in drinking water ^[4]. BPC-157's stability in gastric acid — documented at more than twenty-four hours intact — is the mechanistic basis for oral activity, which distinguishes it from the growth factors (PDGF-BB, EGF) that are rapidly degraded in gastric conditions ^[5][7].

The pharmacokinetic study's route-specific data showed that IM bioavailability in dogs (45–51%) was considerably higher than in rats (14–19%), which illustrates that inter-species pharmacokinetic differences are not trivial and that rodent PK data has limited predictive value for larger mammals, let alone humans, without direct measurement ^[5].

A brief note on stability: the research record indicates that BPC-157 does not require refrigeration or special carrier proteins for stability, unlike many peptides of similar or smaller size. This is consistent with its documented gastric acid resistance.

The research-context framing

This page exists to answer the question that appears most often in BPC-157 searches: what doses does the research actually use? The answer is above — as reported in the cited studies, with their species, routes, and contexts noted.

What this page does not and cannot do is translate those doses into recommendations for human use. BPC-157 has no approved human indication, no FDA-cleared dosing protocol, and no peer-reviewed allometric dose-scaling study bridging rodent data to human pharmacology. The three human pilots that do exist used doses selected empirically — 10 and 20 mg IV in two adults, and 10 mg intravesicularly in twelve adults — without a published dose-rationale methodology ^[14][15].

The Sports Health systematic review's conclusion applies here as directly as anywhere on this site: BPC-157 should not be used clinically until well-designed human trials are conducted ^[16]. The dose data summarized above is the preclinical and pharmacokinetic research record. It is not a protocol.